511 related articles for article (PubMed ID: 21398060)
1. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
[TBL] [Abstract][Full Text] [Related]
2. Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma.
Balbo-Mussetto A; Cirillo S; Bruna R; Gueli A; Saviolo C; Petracchini M; Fornari A; Lario CV; Gottardi D; De Crescenzo A; Tarella C
Clin Radiol; 2016 Mar; 71(3):271-9. PubMed ID: 26749081
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
5. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
[TBL] [Abstract][Full Text] [Related]
6. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
[TBL] [Abstract][Full Text] [Related]
9. Depiction and characterization of liver lesions in whole body [¹⁸F]-FDG PET/MRI.
Beiderwellen K; Gomez B; Buchbender C; Hartung V; Poeppel TD; Nensa F; Kuehl H; Bockisch A; Lauenstein TC
Eur J Radiol; 2013 Nov; 82(11):e669-75. PubMed ID: 24011443
[TBL] [Abstract][Full Text] [Related]
10. Quantitative comparison of pre-therapy
Knešaurek K; Tuli A; Pasik SD; Heiba S; Kostakoglu L
Eur J Radiol; 2018 Dec; 109():57-61. PubMed ID: 30527312
[TBL] [Abstract][Full Text] [Related]
11. Planning transarterial radioembolization of colorectal liver metastases with Yttrium 90 microspheres: evaluation of a sequential diagnostic approach using radiologic and nuclear medicine imaging techniques.
Denecke T; Rühl R; Hildebrandt B; Stelter L; Grieser C; Stiepani H; Werk M; Podrabsky P; Plotkin M; Amthauer H; Ricke J; Lopez Hänninen E
Eur Radiol; 2008 May; 18(5):892-902. PubMed ID: 18175122
[TBL] [Abstract][Full Text] [Related]
12. Respiratory-gated ¹⁸F-FDG PET/CT for the diagnosis of liver metastasis.
Suenaga Y; Kitajima K; Aoki H; Okunaga T; Kono A; Matsumoto I; Fukumoto T; Tanaka K; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1696-701. PubMed ID: 23768610
[TBL] [Abstract][Full Text] [Related]
13. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
14. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
[TBL] [Abstract][Full Text] [Related]
15. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
17. Angiography-based C-arm CT for the assessment of extrahepatic shunting before radioembolization.
Heusner TA; Hamami ME; Ertle J; Hahn S; Poeppel T; Hilgard P; Bockisch A; Forsting M; Antoch G
Rofo; 2010 Jul; 182(7):603-8. PubMed ID: 20183775
[TBL] [Abstract][Full Text] [Related]
18. SPECT/CT with 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer.
Hamami ME; Poeppel TD; Müller S; Heusner T; Bockisch A; Hilgard P; Antoch G
J Nucl Med; 2009 May; 50(5):688-92. PubMed ID: 19372479
[TBL] [Abstract][Full Text] [Related]
19. Computed tomography hepatic arteriography has a hepatic falciform artery detection rate that is much higher than that of digital subtraction angiography and 99mTc-MAA SPECT/CT: implications for planning 90Y radioembolization?
Burgmans MC; Too CW; Kao YH; Goh AS; Chow PK; Tan BS; Tay KH; Lo RH
Eur J Radiol; 2012 Dec; 81(12):3979-84. PubMed ID: 22954411
[TBL] [Abstract][Full Text] [Related]
20. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study.
Smits ML; Nijsen JF; van den Bosch MA; Lam MG; Vente MA; Mali WP; van Het Schip AD; Zonnenberg BA
Lancet Oncol; 2012 Oct; 13(10):1025-34. PubMed ID: 22920685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
